Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Targeting GRB7/ERK/FOXM1 Signaling Pathway Impairs Aggressiveness of Ovarian Cancer Cells

Open access

Abstract

Ovarian cancer is a highly lethal disease with poor prognosis and especially in high-grade tumor. Emerging evidence has reported that aberrant upregulation and activation of GRB7, ERK as well as FOXM1 are closely associated with aggresivenesss of human cancers. However, the interplay between these factors in the pathogenesis of human cancers still remains unclear. In this study, we found that GRB7 (P<0.0001), ERK phosphorylation (P<0.0001) and FOXM1 (P = 0.001) were frequently increased and associated with high-grade tumors, as well as a high tendency in association with advanced stage ovarian cancer by immunohistochemical analysis. Intriguingly, the expressions of GRB7 (P<0.0001), ERK phosphorylation (P<0.001) and FOXM1 (P<0.001) showed a significant stepwise increase pattern along Grade 1 to Grade 3 ovarian cancers. Biochemical studies using western blot analysis demonstrated that enforced expression or knockdown of GRB7 showed GRB7 could elevate the levels of ERK phosphorylation and FOXM1, whereas enforced expression of FOXM1 could not alter levels of GRB7 and ERK phosphorylation. But inhibition of ERK signaling by U0126 or PD98059 could reduce the level of FOXM1 in GRB7-overexpressing ovarian cancer cells, suggesting that GRB7, ERK and FOXM1 are regulated orderly. Moreover, inhibition of ERK activity by U0126 or PD98059, or decreased FOXM1 expression by Thiostrepton significantly inhibited cell migration/invasion, tumor growth in vitro and in vivo. Collectively, our findings confer that targeting GRB7/ERK/FOXM1 signaling cascade may be a promising molecular therapeutic choice in combating ovarian cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0052578

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 A significant stepwise increase in the expressions of GRB7, ERK phosphorylation and FOXM1 along ovarian tumor grade. (A) The expressions of GRB7, ERK phosphorylation and FOXM1 were evaluated by immunohistochemical analysis using specific antibodies on an ovarian cancer tissue array (OVC1021, Pantomics). (B) Representative pictures show the stepwise increase of GRB7, ERK phosphorylation and FOXM1 expressions from Grade 1 to Grade 3 ovarian cancer (serous subtype) (200× magnifications).
Figure 1 A significant stepwise increase in the expressions of GRB7, ERK phosphorylation and FOXM1 along ovarian tumor grade. (A) The expressions of GRB7, ERK phosphorylation and FOXM1 were evaluated by immunohistochemical analysis using specific antibodies on an ovarian cancer tissue array (OVC1021, Pantomics). (B) Representative pictures show the stepwise increase of GRB7, ERK phosphorylation and FOXM1 expressions from Grade 1 to Grade 3 ovarian cancer (serous subtype) (200× magnifications).CC BY · PubMed Central
Figure 2 GRB7/ERK/FOXM1 was regulated in the same signaling axis. (A) Treatment with U0126 (5 µM) showed a significant reduction in the expression of ERK phosphorylation accompanied with FOXM1 in ovarian cancer cells time dependently, whereas no change in GRB7 expression was found in A2780cp cells. (B) Treatment of Thiostrepton (20 µM) remarkably reduced the expression of FOXM1 only but no change in the expressions of GRB7 and ERK phosphorylation in A2780cp cells (left). Depletion of FOXM1 by siRNA knockdown did not alter the expression of GRB7 and ERK phosphorylation (right). C, siRNA scrambled control. si1, si2 and si3 siRNAs targeting three different regions of human FOXM1 and knockdown the expression of FOXM1 by 60%, 45% and 70% respectively. (C) Two out of four GRB7 shRNA constructs (sh1 and sh2) showed ∼70% knockdown of GRB7 accompanied with a reduction of ERK phosphorylation and FOXM1 expressions in OVCA433 cells. The scrambled control (NC) was used as negative control. (D) Enforced expression of GRB7 increased ERK phosphorylation and FOXM1. However, treatment with either U0126 (10 µM) or PD98059 (20 µM) could suppress the induced ERK phosphorylation and FOXM1 in A2780cp and OVCA433 ovarian cancer cells.
Figure 2 GRB7/ERK/FOXM1 was regulated in the same signaling axis. (A) Treatment with U0126 (5 µM) showed a significant reduction in the expression of ERK phosphorylation accompanied with FOXM1 in ovarian cancer cells time dependently, whereas no change in GRB7 expression was found in A2780cp cells. (B) Treatment of Thiostrepton (20 µM) remarkably reduced the expression of FOXM1 only but no change in the expressions of GRB7 and ERK phosphorylation in A2780cp cells (left). Depletion of FOXM1 by siRNA knockdown did not alter the expression of GRB7 and ERK phosphorylation (right). C, siRNA scrambled control. si1, si2 and si3 siRNAs targeting three different regions of human FOXM1 and knockdown the expression of FOXM1 by 60%, 45% and 70% respectively. (C) Two out of four GRB7 shRNA constructs (sh1 and sh2) showed ∼70% knockdown of GRB7 accompanied with a reduction of ERK phosphorylation and FOXM1 expressions in OVCA433 cells. The scrambled control (NC) was used as negative control. (D) Enforced expression of GRB7 increased ERK phosphorylation and FOXM1. However, treatment with either U0126 (10 µM) or PD98059 (20 µM) could suppress the induced ERK phosphorylation and FOXM1 in A2780cp and OVCA433 ovarian cancer cells.CC BY · PubMed Central
Figure 3 Inhibition of ERK phosphorylation or FOXM1 significantly decreased both migration and invasion of GRB7-overexpressing ovarian cancer cells. OVCA433 cells with stable expression of GFP/GRB7 (OVCA433-GRB7) were treated with DMSO as control, Thiostrepton (20 µM), PD98059 (20 µM) and U0126 (10 µM) for 6 hours and were analyzed by (A) Transwell cell migration assay. The representative pictures and bar chart showed significant reduction in the number of migratory cells through Matrigel-coated membrane in OVCA433-GRB7 cells treated with Thiostrepton, PD98059 and U0126 than DMSO control (*P<0.02, Student t-test) at 8-hour; (B) Transwell cell invasion assay. The representative pictures and bar chart showed significant reduction in the invasion rate in OVCA433-GRB7 cells treated with Thiostrepton, PD98059 and U0126 when compared with DMSO control (*P<0.05, Student t-test) at 15-hour.
Figure 3 Inhibition of ERK phosphorylation or FOXM1 significantly decreased both migration and invasion of GRB7-overexpressing ovarian cancer cells. OVCA433 cells with stable expression of GFP/GRB7 (OVCA433-GRB7) were treated with DMSO as control, Thiostrepton (20 µM), PD98059 (20 µM) and U0126 (10 µM) for 6 hours and were analyzed by (A) Transwell cell migration assay. The representative pictures and bar chart showed significant reduction in the number of migratory cells through Matrigel-coated membrane in OVCA433-GRB7 cells treated with Thiostrepton, PD98059 and U0126 than DMSO control (*P<0.02, Student t-test) at 8-hour; (B) Transwell cell invasion assay. The representative pictures and bar chart showed significant reduction in the invasion rate in OVCA433-GRB7 cells treated with Thiostrepton, PD98059 and U0126 when compared with DMSO control (*P<0.05, Student t-test) at 15-hour.CC BY · PubMed Central
Figure 4 Inhibition of either ERK phosphorylation or FOXM1 expression impaired cell growth in ovarian cancer cells. (A) XTT cell proliferation assays showed that the inhibition of ERK phosphorylation by U0126 (10 µM) significantly abrogated the cell proliferation rate in GRB7 stably expressing OVCA433 cells (P = 0.020, Student t-test) and A2780cp cells (P = 0.030, Student t-test) as compared with their vector controls. (B) XTT cell proliferation assays showed that the suppression of FOXM1 expression by Thiostrepton (20 µM) significantly reduced the cell proliferation rate in GRB7 stably expressing OVCA433 cells (P = 0.015, Student t-test) and A2780cp cells (P = 0.025, Student t-test) as compared with their vector controls.
Figure 4 Inhibition of either ERK phosphorylation or FOXM1 expression impaired cell growth in ovarian cancer cells. (A) XTT cell proliferation assays showed that the inhibition of ERK phosphorylation by U0126 (10 µM) significantly abrogated the cell proliferation rate in GRB7 stably expressing OVCA433 cells (P = 0.020, Student t-test) and A2780cp cells (P = 0.030, Student t-test) as compared with their vector controls. (B) XTT cell proliferation assays showed that the suppression of FOXM1 expression by Thiostrepton (20 µM) significantly reduced the cell proliferation rate in GRB7 stably expressing OVCA433 cells (P = 0.015, Student t-test) and A2780cp cells (P = 0.025, Student t-test) as compared with their vector controls.CC BY · PubMed Central
Figure 5 Inhibition of ERK phosphorylation or FOXM1 expression reduced tumor growth in a mouse xenograft model. (A) The GRB7 stably expressing A2780cp cells (Acp-GRB7) were subcutaneously injected into the right flank of nude mice. Mice were divided into 5 groups (5 mice per group) and treated with either DMSO as a control, or U0126 (25 or 50 µM/kg) or Thiostrepton (200 or 300 µM/kg) for every 3-day since on day 6 (Arrows represent the injections). The relative tumor size was calculated relative to those of the first day of treatment (day 0) and are represented as relative mean size (%)±SE for each group (*P = 0. 032, **P<0.01, and ***P = 0. 005, are significantly different from the DMSO control group, Student t-test). (B) The representative pictures and bar charts show the average tumor weight of each group taken on day 18. (*P = 0. 043, **P = 0. 001, and ***P<0.02, are significantly different from the DMSO control group, Student t-test).
Figure 5 Inhibition of ERK phosphorylation or FOXM1 expression reduced tumor growth in a mouse xenograft model. (A) The GRB7 stably expressing A2780cp cells (Acp-GRB7) were subcutaneously injected into the right flank of nude mice. Mice were divided into 5 groups (5 mice per group) and treated with either DMSO as a control, or U0126 (25 or 50 µM/kg) or Thiostrepton (200 or 300 µM/kg) for every 3-day since on day 6 (Arrows represent the injections). The relative tumor size was calculated relative to those of the first day of treatment (day 0) and are represented as relative mean size (%)±SE for each group (*P = 0. 032, **P<0.01, and ***P = 0. 005, are significantly different from the DMSO control group, Student t-test). (B) The representative pictures and bar charts show the average tumor weight of each group taken on day 18. (*P = 0. 043, **P = 0. 001, and ***P<0.02, are significantly different from the DMSO control group, Student t-test).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. CY Koo, 2012, FOXM1: From cancer initiation to progression and treatment, Biochim Biophys Acta, 1819, 28, 10.1016/j.bbagrm.2011.09.004 · DOI · Paper page

Cited by

See all 52

Metadata

Authors
Chan, D. W., Hui, W. W. Y., Cai, P. C. H., Liu, M. X., Yung, M. M. H., Mak, C. S. L., Leung, T. H. Y., Chan, K. K. L., & Ngan, H. Y. S.
Affiliations
University of Hong Kong (HK)
Corresponding author
Chan, David W.
Venue
PLoS ONE
Published
2012-12-20
Volume
7
Issue
12
Pages
e52578
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2000095065
Cited by
51
References
50
Citations by year
2026: 1 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 6 · 2020: 7 · 2019: 2 · 2018: 1 · 2017: 8 · 2016: 3 · 2015: 6 · 2014: 5 · 2013: 6
FWCI
6.35
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
Keywords
ovarian cancer, Grb7, ERK1/2 phosphorylation, FOXM1, tumor aggressiveness, tumor grade, cell migration and invasion, tumor growth, ERK inhibition, thiostrepton, U0126, PD98059, molecular therapy
MeSH terms
Forkhead Box Protein M1, Animals, Cell Movement, Female, Humans, Mice, Inbred BALB C, Neoplasm Invasiveness, Ovarian Neoplasms, Phosphorylation, Signal Transduction, Xenograft Model Antitumor Assays, Cell Line, Tumor, Extracellular Signal-Regulated MAP Kinases, Cell Proliferation, Mice, GRB7 Adaptor Protein, Forkhead Transcription Factors, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.